# A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care

> **NCT00071799** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 358 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Azacitidine
- **OTHER:** Physician Choice

## Key facts

- **NCT ID:** NCT00071799
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11-01
- **Primary completion:** 2007-07-01
- **Final completion:** 2007-07-01
- **Target enrollment:** 358 (ACTUAL)
- **Last updated:** 2019-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00071799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00071799, "A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00071799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*